Loading...
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die...
Saved in:
| Published in: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Berlin Heidelberg
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5854713/ https://ncbi.nlm.nih.gov/pubmed/29464354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3532-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|